Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
Cancers|April 27, 2024
Th2 Cells Are Associated with Tumor Recurrence Following RadiationMohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, et al.
Cancer Immunology Research|April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)Tara C Mitchell, Omid Hamid, David C Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibitionRobert Ferguson, Vylyny Chat, Leah Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasFunda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaRyan C Augustin, Sarah Newman, Aofei Li, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
Pageof 19